MedTrace Logo

Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control

NCT00698932 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 568

Last updated 2011-09-21

Study results available
· View outcomes & findings →

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and exercise.

Conditions

Interventions

DRUG

Saxagliptin

5mg, oral tablet, once daily for 24 weeks

DRUG

Placebo

oral tablet, once daily for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Peter Öhman, MD, PhD · AstraZeneca, Wilmington, USA

  • Deborah Price, MSc · AstraZeneca, Wilmington, USA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • China
  • India
  • Philippines
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00698932 on ClinicalTrials.gov